tetano
Editor, Senior Moderator
Zhonghua Liu Xing Bing Xue Za Zhi. 2010 May;31(5):481-484.
[Safety and epidemiological effects of the first China-made mass A (H1N1) influenza vaccination.]
[Article in Chinese]
Ji WY, Lu L, L? M, Miao L, Gao T, Huang RG, Suo LD, Liu DL, Ma R, Yu R, Zhangzhu JZ, Liu WX, Zeng Y, Li XM, Wu J.
Beijing Center for Disease Control and Prevention, Beijing 100013, China.
Abstract
OBJECTIVE: To evaluate the safety and epidemiological effects on the first mass vaccination program, using the China-made A (H1N1) influenza vaccine.
METHODS: Descriptive epidemiology and cohort study design were used to assess the influenza A H1N1 vaccine on its safety and epidemiological effects.
RESULTS: 95 244 subjects were immunized with A (H1N1) influenza vaccine. 193 adverse events were reported through AEFI Management System, with the Reported rates of AEFI as 2.03?. Most of the adverse events (137/193, 71.0%) happened during the first 24 hours after immunization was carried out. Of 81 adverse reactions confirmed to be related to immunization, with 78 (96.3%) showed mild reactions. No Guillain-Barre Syndrome related to vaccination was reported through the AEFI Management System. The epidemiological protection rate of A (H1N1) vaccine could reach 80.9% when the coverage was not considered.
CONCLUSION: The A (H1N1) influenza vaccine showed a similar safety profile to seasonal flu vaccine. The vaccine demonstrated a good epidemiological effects against A (H1N1) influenza virus infection.
PMID: 21163019 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21163019
[Safety and epidemiological effects of the first China-made mass A (H1N1) influenza vaccination.]
[Article in Chinese]
Ji WY, Lu L, L? M, Miao L, Gao T, Huang RG, Suo LD, Liu DL, Ma R, Yu R, Zhangzhu JZ, Liu WX, Zeng Y, Li XM, Wu J.
Beijing Center for Disease Control and Prevention, Beijing 100013, China.
Abstract
OBJECTIVE: To evaluate the safety and epidemiological effects on the first mass vaccination program, using the China-made A (H1N1) influenza vaccine.
METHODS: Descriptive epidemiology and cohort study design were used to assess the influenza A H1N1 vaccine on its safety and epidemiological effects.
RESULTS: 95 244 subjects were immunized with A (H1N1) influenza vaccine. 193 adverse events were reported through AEFI Management System, with the Reported rates of AEFI as 2.03?. Most of the adverse events (137/193, 71.0%) happened during the first 24 hours after immunization was carried out. Of 81 adverse reactions confirmed to be related to immunization, with 78 (96.3%) showed mild reactions. No Guillain-Barre Syndrome related to vaccination was reported through the AEFI Management System. The epidemiological protection rate of A (H1N1) vaccine could reach 80.9% when the coverage was not considered.
CONCLUSION: The A (H1N1) influenza vaccine showed a similar safety profile to seasonal flu vaccine. The vaccine demonstrated a good epidemiological effects against A (H1N1) influenza virus infection.
PMID: 21163019 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21163019